Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States

Cell Systems

Volumn 5, Issue 2, 2017, Pages 105-118.e9

  Kim, Jong Wook ^a,b,c   Abudayyeh, Omar O ^a   Yeerna, Huwate ^h   Yeang, Chen Hsiang ^a,d   Stewart, Michelle ^a   Jenkins, Russell W ^b   Kitajima, Shunsuke ^b   Konieczkowski, David J ^a,i   Medetgul Ernar, Kate ^h   Cavazos, Taylor ^h   Mah, Clarence ^g,h   Ting, Stephanie ^h   Van Allen, Eliezer M ^a,b   Cohen, Ofir ^a,b   Mcdermott, John ^a   Damato, Emily ^a   Aguirre, Andrew J ^a,b,c   Liang, Jonathan ^a   Liberzon, Arthur ^a   Alexe, Gabriella ^a,b,e,f   Doench, John ^a   Ghandi, Mahmoud ^a   Vazquez, Francisca ^a,b   Weir, Barbara A ^a   Tsherniak, Aviad ^a   Subramanian, Aravind ^a   Meneses Cime, Karina ^h   Park, Jason ^h   Clemons, Paul ^a   Garraway, Levi A ^a,b,c   Thomas, David ^a   Boehm, Jesse S ^a   Barbie, David A ^a,b   Hahn, William C ^a,b,c   Mesirov, Jill P ^a,g,h   Tamayo, Pablo ^a,g,h   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f BOSTON UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bayesian nomogram; cellular states; drug sensitivity; genetic dependency; inferential model; matrix factorization; oncogenic pathway; oncoGPS; precision medicine; transcriptional signatures

Indexed keywords

LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; TUMOR MARKER;

ARTICLE; CLINICAL RESEARCH; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENE SEQUENCE; HUMAN; MELANOMA; ONCOGENE; ONCOGENE K RAS; OVERLAPPING GENE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; TRANSCRIPTION REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOME; MAPK SIGNALING; METABOLISM; NEOPLASM; ONCOGENE RAS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENOME; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PRECISION MEDICINE;

EID: 85028340650     PISSN: 24054712     EISSN: 24054720     Source Type: Journal    
DOI: 10.1016/j.cels.2017.08.002     Document Type: Article

References (71)

1. Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26 (2007), 6979–6988.
2. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
3. Barbie, T.U., Alexe, G., Aref, A.R., Li, S., Zhu, Z., Zhang, X., Imamura, Y., Thai, T.C., Huang, Y., Bowden, M., et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J. Clin. Invest. 124 (2014), 5411–5423.
4. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
5. Bild, A.H., Yao, G., Chang, J.T., Wang, Q., Potti, A., Chasse, D., Joshi, M.B., Harpole, D., Lancaster, J.M., Berchuck, A., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006), 353–357.
6. Brunet, J.P., Tamayo, P., Golub, T.R., Mesirov, J.P., Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. USA 101 (2004), 4164–4169.
7. Chamorro, M.N., Schwartz, D.R., Vonica, A., Brivanlou, A.H., Cho, K.R., Varmus, H.E., FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J. 24 (2005), 73–84.
8. Chang, J.T., Carvalho, C., Mori, S., Bild, A.H., Gatza, M.L., Wang, Q., Lucas, J.E., Potti, A., Febbo, P.G., West, M., et al. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol. Cell 34 (2009), 104–114.
9. Cheung, H.W., Cowley, G.S., Weir, B.A., Boehm, J.S., Rusin, S., Scott, J.A., East, A., Ali, L.D., Lizotte, P.H., Wong, T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 108 (2011), 12372–12377.
10. Cichocki, A., Zdunek, R., Amari, S., Nonnegative Matrix and Tensor Factorization. 2008, IEEE Signal Processing Magazine, 142–145.
11. Cowley, G.S., Weir, B.A., Vazquez, F., Tamayo, P., Scott, J.A., Rusin, S., East-Seletsky, A., Ali, L.D., Gerath, W.F., Pantel, S.E., et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data, 1, 2014, 140035.
12. Dawson, M.A., Kouzarides, T., Cancer epigenetics: from mechanism to therapy. Cell 150 (2012), 12–27.
13. De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J.L., Mautner, V., Kehrer-Sawatzki, H., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514 (2014), 247–251.
14. Downward, J., RAS synthetic lethal screens revisited: still seeking the elusive prize?. Clin. Cancer Res. 21 (2015), 1802–1809.
15. Elenbaas, B., Spirio, L., Koerner, F., Fleming, M.D., Zimonjic, D.B., Donaher, J.L., Popescu, N.C., Hahn, W.C., Weinberg, R.A., Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 (2001), 50–65.
16. Fan, R.-E., Chen, P.-H., Lin, C.-J., Working set selection using second order information for training support vector machines. J. Mach. Learn. Res. 6 (2005), 1889–1918.
17. Feng, D., Tierney, L., Computing and displaying isosurfaces in R. J. Stat. Softw. 28 (2008), 1–24.
18. Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363 (2010), 809–819.
19. Fultz, B., Phase Transitions in Materials. 2014, Cambridge University Press.
20. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
21. Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
22. Good, I.J., Weight of evidence: a brief survey. Bayesian Stat. 2 (1985), 249–270.
23. Groger, C.J., Grubinger, M., Waldhor, T., Vierlinger, K., Mikulits, W., Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One, 7, 2012, e51136.
24. Hartigan, J.A., Clustering algorithms. Bradley, R.A., Kendall, D.G., Hunter, J.S., Watson, G.S., (eds.) Information Retrieval: Data Structures and Algorithms, Vol. 2, 1975, John Wiley & Sons, 419–442.
25. Hinata, K., Gervin, A.M., Jennifer Zhang, Y., Khavari, P.A., Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene 22 (2003), 1955–1964.
26. Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158 (2014), 929–944.
27. Hofmann-Wellenhof, B., Lichtenegger, H. & Wasle, E. (2007). GNSS – Global Navigation Satellite Systems – GPS, GLONASS, Galileo, etc.
28. Hopewell, E.L., Zhao, W., Fulp, W.J., Bronk, C.C., Lopez, A.S., Massengill, M., Antonia, S., Celis, E., Haura, E.B., Enkemann, S.A., et al. Lung tumor NF-kappaB signaling promotes T cell-mediated immune surveillance. J. Clin. Invest. 123 (2013), 2509–2522.
29. Hyman, D.M., Puzanov, I., Subbiah, V., Faris, J.E., Chau, I., Blay, J.Y., Wolf, J., Raje, N.S., Diamond, E.L., Hollebecque, A., et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373 (2015), 726–736.
30. Jané-Valbuena, J., Widlund, H.R., Perner, S., Johnson, L.A., Dibner, A.C., Lin, W.M., Baker, A.C., Nazarian, R.M., Vijayendran, K.G., Sellers, W.R., et al. An oncogenic role for ETV1 in melanoma. Cancer Res. 70 (2010), 2075–2084.
31. Joe, H., Relative entropy measures of multivariate dependence. J. Am. Stat. Assoc. 84 (1989), 157–164.
32. Kim, J.W., Botvinnik, O.B., Abudayyeh, O., Birger, C., Rosenbluh, J., Shrestha, Y., Abazeed, M.E., Hammerman, P.S., DiCara, D., Konieczkowski, D.J., et al. Characterizing genomic alterations in cancer by complementary functional associations. Nat. Biotechnol. 34 (2016), 539–546.
33. Kirzin, S., Marisa, L., Guimbaud, R., De Reynies, A., Legrain, M., Laurent-Puig, P., Cordelier, P., Pradere, B., Bonnet, D., Meggetto, F., et al. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PLoS One, 9, 2014, e103159.
34. Konieczkowski, D.J., Johannessen, C.M., Abudayyeh, O., Kim, J.W., Cooper, Z.A., Piris, A., Frederick, D.T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 4 (2014), 816–827.
35. Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Janne, P.A., Costa, D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363 (2010), 1693–1703.
36. Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., Tamayo, P., The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1 (2015), 417–425.
37. Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdottir, H., Tamayo, P., Mesirov, J.P., Molecular Signatures Database (MSigDB) 3.0. Bioinformatics 27 (2011), 1739–1740.
38. Lin, J., Divergence measures based on the Shannon entropy. IEEE Trans. Inform. Theor. 37 (1991), 145–151.
39. Linfoot, E.H., An informational measure of correlation. Inf. Control 1 (1957), 85–89.
40. Lundberg, A.S., Randell, S.H., Stewart, S.A., Elenbaas, B., Hartwell, K.A., Brooks, M.W., Fleming, M.D., Olsen, J.C., Miller, S.W., Weinberg, R.A., et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21 (2002), 4577–4586.
41. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
42. Manchado, E., Weissmueller, S., Morris, J.P. 4th, Chen, C.C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J.T., Gainor, J.F., Corcoran, R.B., et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534 (2016), 647–651.
43. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20 (2010), 1297–1303.
44. Monti, S., Tamayo, P., Mesirov, J., Golub, T.R., Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learn. 52 (2003), 91–118.
45. Mozina, M., Demšar, J., Kattan, M., Zutan, B., Nomograms for visualization of naive Bayesian classifier. Lect. Notes Comput. Sci. 3202 (2004), 337–348.
46. Peck, D., Crawford, E.D., Ross, K.N., Stegmaier, K., Golub, T.R., Lamb, J., A method for high-throughput gene expression signature analysis. Genome Biol., 7, 2006, R61.
47. Pott, S., Lieb, J.D., What are super-enhancers?. Nat. Genet. 47 (2015), 8–12.
48. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., Bernards, R., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483 (2012), 100–103.
49. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., Rosen, N., (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 106 (2009), 4519–4524.
50. Salt, M.B., Bandyopadhyay, S., McCormick, F., Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 4 (2014), 186–199.
51. Scott, D.W., Multivariate Density Estimation. Mortality. 1997, Rice University, 1–11.
52. Seashore-Ludlow, B., Rees, M.G., Cheah, J.H., Cokol, M., Price, E.V., Coletti, M.E., Jones, V., Bodycombe, N.E., Soule, C.K., Gould, J., et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5 (2015), 1210–1223.
53. Seo, J.S., Ju, Y.S., Lee, W.C., Shin, J.Y., Lee, J.K., Bleazard, T., Lee, J., Jung, Y.J., Kim, J.O., Shin, J.Y., et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22 (2012), 2109–2119.
54. Serresi, M., Gargiulo, G., Proost, N., Siteur, B., Cesaroni, M., Koppens, M., Xie, H., Sutherland, K.D., Hulsman, D., Citterio, E., et al. Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29 (2016), 17–31.
55. Sethna, J.P., Entropy, Order Parameters and Complexity. In Complexity. 2011, Oxford University Press, 376.
56. Shao, D.D., Xue, W., Krall, E.B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A.C., Sood, S., Rosenbluh, J., Kim, J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158 (2014), 171–184.
57. Sheather, S.J., Density estimation. Stat. Sci. 19 (2004), 588–597.
58. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., Settleman, J., A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15 (2009), 489–500.
59. Singh, A., Sweeney, M.F., Yu, M., Burger, A., Greninger, P., Benes, C., Haber, D.A., Settleman, J., TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148 (2012), 639–650.
60. Skoulidis, F., Byers, L.A., Diao, L., Papadimitrakopoulou, V.A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E.R., Canales, J.R., et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5 (2015), 860–877.
61. Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7 (2014), 86–93.
62. Tamayo, P., Cho, Y.J., Tsherniak, A., Greulich, H., Ambrogio, L., Schouten-van Meeteren, N., Zhou, T., Buxton, A., Kool, M., Meyerson, M., et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J. Clin. Oncol. 29 (2011), 1415–1423.
63. Tamayo, P., Scanfeld, D., Ebert, B.L., Gillette, M.A., Roberts, C.W., Mesirov, J.P., Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc. Natl. Acad. Sci. USA 104 (2007), 5959–5964.
64. Taube, J.H., Herschkowitz, J.I., Komurov, K., Zhou, A.Y., Gupta, S., Yang, J., Hartwell, K., Onder, T.T., Gupta, P.B., Evans, K.W., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107 (2010), 15449–15454.
65. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
66. Torres-García, W., Zheng, S., Sivachenko, A., Vegesna, R., Wang, Q., Yao, R., Berger, M.F., Weinstein, J.N., Getz, G., Verhaak, R.G., PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30 (2014), 2224–2226.
67. Venables, W.N., Ripley, B.D., Modern Applied Statistics with S. Issues of Accuracy and Scale. 2002, Springer, 868.
68. Wood, K.C., Konieczkowski, D.J., Johannessen, C.M., Boehm, J.S., Tamayo, P., Botvinnik, O.B., Mesirov, J.P., Hahn, W.C., Root, D.E., Garraway, L.A., et al. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci. Signal., 5, 2012, rs4.
69. Yang, W., Soares, J., Greninger, P., Edelman, E.J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J.A., Thompson, I.R., et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41:Database issue (2013), D955–D961.
70. Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 (2012), 656–670.
71. Zhu, Z., Aref, A.R., Cohoon, T.J., Barbie, T.U., Imamura, Y., Yang, S., Moody, S.E., Shen, R.R., Schinzel, A.C., Thai, T.C., et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 4 (2014), 452–465.